about
Antituberculosis therapy for 2012 and beyondStructural features and kinetic characterization of alanine racemase fromStaphylococcus aureus(Mu50)Newer antibacterial drugs for a new century.Population pharmacokinetic and pharmacodynamic analysis of linezolid and a hematologic side effect, thrombocytopenia, in Japanese patients.High plasma linezolid concentration and impaired renal function affect development of linezolid-induced thrombocytopenia.Efficacy of linezolid on gram-positive bacterial infection in elderly patients and the risk factors associated with thrombocytopenia.Linezolid for the treatment of multidrug-resistant tuberculosis.Risk of serotonin syndrome with concomitant administration of linezolid and serotonin agonists.Rapid bactericidal activity of daptomycin against methicillin-resistant and methicillin-susceptible Staphylococcus aureus peritonitis in mice as measured with bioluminescent bacteria.Effect of oral linezolid on the pressor response to intravenous tyramine.Clinical update on linezolid in the treatment of Gram-positive bacterial infections.A guide to antibiotic resistance in bacterial skin infections.Use of linezolid in children: an overview of recent advances.Emerging options for treatment of invasive, multidrug-resistant Staphylococcus aureus infections.Susceptibility profile of methicillin-resistant Staphylococcus aureus to linezolid in clinical isolates.Activity of daptomycin or linezolid in combination with rifampin or gentamicin against biofilm-forming Enterococcus faecalis or E. faecium in an in vitro pharmacodynamic model using simulated endocardial vegetations and an in vivo survival assay usiFront-loaded linezolid regimens result in increased killing and suppression of the accessory gene regulator system of Staphylococcus aureus.Experience with ceftaroline for treatment of methicillin-resistant Staphylococcus aureus pneumonia in a community hospital.Mitochondrial Alterations (Inhibition of Mitochondrial Protein Expression, Oxidative Metabolism and Ultrastructure) Induced by Linezolid and Tedizolid at Clinically-relevant Concentrations in cultured Human HL-60 promyelocytes and THP-1 monocytes.Comprehensive review of cardiovascular toxicity of drugs and related agents.History of antibiotics: from fluoroquinolones to daptomycin (Part 2).Linezolid: a review of its properties, function, and use in critical care.
P2860
Q26829101-A9FFB34D-4EC1-41FA-B7FD-7EAFEEA30179Q27676379-AB20615D-5399-433B-9139-4F38FB43B13CQ30433333-A7BF7686-B15E-4E72-8A77-6671210FEF09Q33394332-23321575-0164-4A35-A649-0EDA88173693Q33407349-712E1439-0C9D-411A-A5C8-2E3370B698FDQ33412202-B6D0078C-EEDE-4331-A978-4667460F8F72Q34420818-68F90FE8-0076-4D75-AABB-1D92E3DF59F2Q34584411-551E7098-56F3-476F-B6B1-E468E5E68BC5Q35759049-7E72F76E-08DF-4E14-984A-1FF7CF98C22FQ35826505-B15ADB77-3224-40BE-BC76-427C30C52188Q36083208-730C5C0A-0E46-4ADA-B28F-942026992E8DQ36258130-1C506CEF-031D-4678-9312-8FCCB890C0E4Q36688930-15BD3FDB-5A77-4F05-B12A-F91CA92898D4Q36718474-6EF31494-D092-4A1A-9FD3-94EA52520FC2Q37668638-4EB99010-298E-4186-B41D-D516B399649AQ42003344-63D498F3-AA4B-45C7-BF10-C7F212B769EDQ42110580-A274E7B4-E488-4076-BB0C-83326C9E7D38Q44726399-3DF822B0-EBDE-40D3-8B64-96B4BCED5E4AQ47269635-544FEA1E-F9E9-47E9-AC33-BBA8513B735BQ47556269-8771C7AC-0689-4861-9B04-46CA52F890E6Q48202873-A68DF5CA-E105-4732-B02C-3FAF88FD5C7DQ55368160-18C67893-806F-47A2-92D8-58DEEAEA6717
P2860
description
2003 nî lūn-bûn
@nan
2003 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Safety and tolerability of linezolid.
@ast
Safety and tolerability of linezolid.
@en
type
label
Safety and tolerability of linezolid.
@ast
Safety and tolerability of linezolid.
@en
prefLabel
Safety and tolerability of linezolid.
@ast
Safety and tolerability of linezolid.
@en
P356
P1476
Safety and tolerability of linezolid.
@en
P2093
Gary French
P304
P356
10.1093/JAC/DKG253
P407
P478
51 Suppl 2
P577
2003-05-01T00:00:00Z